Chaoping Fu

An injectable dual-crosslinked HTCC/F127-CHO hydrogel integrates sustained EGF release, antibacterial activity, and tissue adhesion to accelerate diabetic wound healing via simultaneous infection control and tissue regeneration.

The treatment of solid tumors with chimeric antigen receptor natural killer (CAR-NK) cell therapy confronts significant barriers, notably poor cellular inf

Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation, chronic inflammation, and subchondral bone remodeling. Conventional intra‐articular therapies provide limited relief and fail to address its multifactorial pathogenesis. Here, we present an injectable hydrogel microsphere platform that integrates antioxidative, anti‐inflammatory, and regenerative functions for localized OA management. Uniform (∼125 µm) chondroitin sulfate methacrylate (ChSMA)‐based microspheres are fabricated via microfluidic photocross‐linking. Manganese dioxide nanoparticles provided catalytic reactive oxygen species (ROS) scavenging, while dexamethasone sodium phosphate enabled sustained release, reducing TNF‐α and IL‐6 levels by ∼30%. Bone marrow mesenchymal stem cells (BMSCs) are co‐delivered to promote cartilage repair. In vitro, the microspheres reduce intracellular ROS, induce M2 macrophage polarization, and suppress inflammatory cytokines by 60–70%, with IL‐10 levels increased by ∼90%. 3D co‐culture supports chondrocyte/BMSC viability and matrix production. In vivo, intra‐articular injection in a rat OA model markedly reduces cartilage erosion, decreases osteophyte volume by 80%, and improves subchondral bone microarchitecture. Histological staining confirms matrix restoration and structural preservation, with Osteoarthritis Research Society International (OARSI) scores reduced by 88%. Collectively, this injectable hydrogel microsphere system offers a minimally invasive and integrated strategy, simultaneously delivering antioxidative, anti‐inflammatory, and regenerative effects for comprehensive OA management.

全无机CsPbBr3钙钛矿太阳能电池因优异的环境稳定性备受关注，但其效率与理论极限仍存在显著差距。电子传输层与钙钛矿薄膜间的界面缺陷，以及二者存在的能级失配现象，是限制其性能提升的主要原因之一。本文采用碱金属氟化物(NaF、KF、RbF、CsF)对TiO2电子传输层进行界面修饰，系统研究其对TiO2/CsPbBr3埋底界面及其器件性能表现的影响。实验表明，CsF修饰可协同钝化TiO2表面氧空位(通过F⁻与Ti⁴⁺键合)和CsPbBr3的A位阳离子空位(通过Cs⁺填补)，显著降低界面缺陷态密度，优化能级匹配。优化后的器件光电转换效率(power conversion efficiency, PCE)从7.71%提升至10.52%，开路电压(open circuit voltage, VOC)达到1.63 V，填充因子(fill factor, FF)提高至83.38%。此外，未封装器件在室温环境下老化30天后仍保持初始效率的90%，展现出优异的长期稳定性。本研究通过阴阳离子协同钝化与能带工程的双重策略，为高效稳定全无机钙钛矿太阳能电池的开发提供了新思路。

Postoperative wound management remains clinically challenging due to delayed healing, subcutaneous infections, and the absence of systems capable of real-time therapeutic and diagnostic integration. Addressing this need, we developed a bioactive, self-adaptive hydrogel platform that combines electrical stimulation (ES) therapy with resistance-based bioelectronic sensing for personalized postoperative wound care. The hydrogel is constructed from dynamic borate ester-cross-linked poly(vinyl alcohol) (PVA), with wool keratin for hemostasis and tissue remodeling and tannic acid for adhesion, antioxidative protection, and enhanced biocompatibility. This composition imparts excellent stretchability, self-healing ability, and conformal adaptability to irregular wound sites. Upon application, the platform delivers uniform ES to promote angiogenesis and re-epithelialization, achieving a 99.96% wound closure rate in vivo by day 14. Simultaneously, the system enables noninvasive clinical monitoring by capturing resistance signals that reflect healing status. Actively recovering wounds exhibited relative resistance changes of approximately 200% compared with the preoperative skin condition, while infected sites with subcutaneous abscesses showed reductions to less than 50% of the preoperative skin values. Fully healed tissues, measured 3 weeks post discharge, displayed resistance levels nearly identical to the preoperative skin condition. These findings validate the platform's dual therapeutic and sensing capabilities and demonstrate its translational potential for smart, data-driven postoperative wound care.

Compared to conventional two-dimensional (2D) or scaffold-free three-dimensional (3D) drug screening models, biomimetic osteochondral constructs offer superior physiological relevance for studying osteoarthritis (OA) and accelerating therapeutic discovery. Herein, we report the development of a polymeric microarchitecture (PM)-based 3D osteochondral model for drug screening applications. Microfluidics-assisted fabrication enabled the generation of cartilage-like and osteogenic microtissues by encapsulating chondrocytes and endothelial/osteoblast cells within PMs. These multicellular aggregates were embedded in gelatin methacryloyl (GelMA) and assembled via 3D bioprinting into a stratified osteochondral construct. The model exhibited favorable cell viability, proliferation, and organized microtissue formation, validating its biological functionality. An OA-like microenvironment was induced with lipopolysaccharide (LPS), which significantly elevated pro-inflammatory cytokines. Treatment with diclofenac, dexamethasone, or curcumin markedly attenuated this response, reducing TNF-α, IL-1β, and IL-6 to 42.1, 193.5, and 193.5 pg/mL, respectively, while elevating the anti-inflammatory cytokine IL-10 to 90.2 pg/mL. Overall, this PM-supported 3D osteochondral platform reproduces key features of native joint tissue and holds promise for OA research, drug screening, and regenerative medicine.